Gallagher John E 4

What Happened

• John E. Gallagher, Executive Vice President & CFO of CONMED Corporation (CNMD), received three equity awards on July 15, 2026 totaling 92,465 derivative shares (35,054 + 26,875 + 30,536). Each award shows an acquisition price of $0, indicating compensation grants (not open-market purchases or sales). These awards were reported on a Form 4 filed July 17, 2026.
• The awards include restricted stock units (RSUs) and stock options granted under CONMED’s 2025 Long-Term Incentive Plan. No shares were sold or exercised in this filing—this is a grant/compensation event rather than an investment purchase.

Key Details

• Transaction date: 2026-07-15; Form 4 filed: 2026-07-17 (timely filing).
• Award amounts: 35,054; 26,875; and 30,536 shares — total 92,465 derivative shares. Reported acquisition price: $0.00 (award).
• Vesting (per footnotes):
  • RSUs: generally vest over three years (33% at 1 year, 33% at 2 years, 34% at 3 years).
  • Stock options: generally vest in equal amounts over four years (25% at 1 year, then quarterly/annually thereafter as specified).
• Shares owned after transaction: not provided in the supplied excerpt.
• No 10b5-1 plan, tax-withholding sale, cashless exercise, or late-filing flag was indicated in the provided details.

Context

• These awards are standard long-term incentive compensation for executives and are common as retention and performance incentives; they do not represent a market purchase by the insider. RSUs are a contingent right to receive shares upon vesting; stock options give the right to buy shares if and when vested and exercised (exercise price not specified in the excerpt).
• For retail investors, awards signal company compensation decisions but are not a straightforward bullish/bearish signal like a direct purchase or sale.